Pulmonary Fibrosis Treatments: Cellcept
Mycophenolate Mofetil (Cellcept)
Rituximab (RTX) as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease (SSc-ILD) unresponsive to conventional immunosuppression. Based on our results, RTX's use as an add-on treatment to MMF appears to be effective as a rescue therapy in patients with a more aggressive SSc-ILD phenotype. Seminars in Arthritis and Rheumatism, 08/08/2020. (Also see Biologic Agents)
Treatment With Mycophenolate (MMF) and Cyclophosphamide (CYC) Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease (SSc-ILD). Treatment with CYC and MMF improved overall health-related quality of life in patients with SSc-ILD. PubMed, ACR Open Rheumatol, 05/20/2020. (Also see Cyclophosphamide)
Using transitional changes on HRCT to monitor the impact of cyclophosphamide or mycophenolate on systemic sclerosis-related interstitial lung disease (SSc-ILD). Significantly favorable transitions from both ground glass and lung fibrosis ILD patterns to normal lung were found in patients undergoing immunosuppressive treatment for Ssc-ILD. PubMed, Arthritis Rheumatol, 08/20/2019. (Also see Cyclophosphamide)
Scleroderma Lung Study II. This study compares 2 different medications—daily oral cyclophosphamide (CYC) with daily oral mycophenolate mofetil (MMF, also called CellceptTM) in the treatment of scleroderma-related pulmonary fibrosis. There are twelve study centers across the U.S. University of California. (Also see Pulmonary Fibrosis, Cyclophosphamide, and Clinical Trials)
We have the world's best supporters! See ISN News.
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:
7455 France Ave So #266
Edina, MN 55435-4702 USA